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Abstract
The JmjC domain-containing protein JMJD3/KDM6B catalyses the demethylation of H3K27me3 and H3K27me2. JMJD3
appears to be highly regulated at the transcriptional level and is upregulated in response to diverse stimuli such as
differentiation inducers and stress signals. Accordingly, JMJD3 has been linked to the regulation of different biological
processes such as differentiation of embryonic stem cells, inflammatory responses in macrophages, and induction of cellular
senescence via regulation of the INK4A-ARF locus. Here we show here that JMJD3 interacts with the tumour suppressor
protein p53. We find that the interaction is dependent on the p53 tetramerization domain. Following DNA damage, JMJD3
is transcriptionally upregulated and by performing genome-wide mapping of JMJD3, we demonstrate that it binds genes
involved in basic cellular processes, as well as genes regulating cell cycle, response to stress and apoptosis. Moreover, we
find that JMJD3 binding sites show significant overlap with p53 bound promoters and enhancer elements. The binding of
JMJD3 to p53 target sites is increased in response to DNA damage, and we demonstrate that the recruitment of JMJD3 to
these sites is dependent on p53 expression. Therefore, we propose a model in which JMJD3 is recruited to p53 responsive
elements via its interaction with p53 and speculate that JMJD3 could act as a fail-safe mechanism to remove low levels of
H3K27me3 and H3K27me2 to allow for efficient acetylation of H3K27.
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Introduction
The N-terminal tails of histone proteins are subject to various
post-translational modifications including methylation of lysine
residues. The combination of histone modifications affects
chromatin structure and can determine transcriptional outcome.
In addition, histone modifications have been implicated in the
regulation of genomic stability and cell fate decisions, as well as
pathological processes such as cancer development.
Di- and tri-methylation of histone 3 lysine 27 (H3K27me2/
me3) is catalysed by the Polycomb Repressive Complex 2 (PRC2),
and is associated with transcriptional repression. The Polycomb
group (PcG) proteins are essential for normal development in
Drosophila and mammals, and are found as key regulators of genes
involved in cellular differentiation and stem cell identity [1–4]. In
addition, PcG proteins can repress the expression of certain
tumour suppressor genes, including the INK4A-ARF locus [5–8]
and overexpression of PcG proteins has been implicated in cancer
development [9,10].
The JmjC domain containing proteins JMJD3/KDM6B and
UTX/KDM6A are H3K27me2/me3 specific demethylases [11–
15]. With the ability to revert PcG mediated repression, the
proteins are potential mediators of differentiation and develop-
ment. In agreement with this, the C. elegans UTX and JMJD3
homologs are required for normal gonadal development in the
worm [11,16] and inhibition of Utx1 expression in zebrafish
results in improper posterior development [14]. Unlike UTX,
JMJD3 appears to be highly regulated at the transcriptional level
and is upregulated in response to diverse stimuli such as
differentiation inducers and stress signals. For instance, JMJD3 is
dynamically expressed during differentiation of embryonic stem
cells [17] and keratinocytes [18], and is highly upregulated in
inflammatory stimulated bone marrow-derived macrophages
[12,19]. Furthermore, JMJD3 possesses tumour suppressor char-
acteristics and is upregulated in response to oncogenic stress,
where it contributes to activation of the INK4A-ARF locus [20,21].
Trp53, the p53 tumour suppressor gene, is frequently mutated in
human cancer. In unstressed cells, p53 levels are kept low by the
negative regulator MDM2, which is an E3 ubiquitin ligase that
binds and targets p53 for proteosomal degradation [22]. However,
in response to stress signals, such as DNA damage, p53 is subject
to post-translational modifications including phosphorylation,
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which reduces its affinity for MDM2 leading to stabilization of the
protein. Release of p53 from MDM2 allows it to function as a
transcription factor, where it binds to DNA as a tetramer leading
to activation of multiple target genes involved in processes like cell
cycle arrest, apoptosis, senescence and DNA repair [23]. Most
cancer derived p53 mutations are found within the DNA binding
domain [24], suggesting that the main tumour suppressing role of
p53 is based on its ability to function as a transcription factor.
However, it is now evident that p53 signalling is mediated at
several levels and that it also has cytoplasmic roles, where it can
function in the regulation of apoptosis and autophagy [25].
The exact mechanism by which p53 discriminates between
different cell fates in response to numerous types of stress is still an
open question. There appears to be a complex network of
signalling pathways involved in the regulation of p53 protein
stability and p53 signalling pathways. p53 is subject to various
post-translational modifications including phosphorylation, ubi-
quitination and methylation, and it has been reported to associate
with several different binding partners [26], which could all
contribute to selectively target p53 to certain genes.
Consistent with recent reports [27–29] we show here that
JMJD3 interacts with p53. By performing genome-wide mapping
of JMJD3 and p53, we find that JMJD3 binding shows significant
overlap with p53 targeted sites. We find that the binding of JMJD3
to p53 bound promoters, as well as p53 associated enhancer
elements, is increased in response to DNA damage and
demonstrate that the recruitment of JMJD3 to these sites is
dependent on p53.
Results
JMJD3 associates with p53
To gain information regarding the functional role of JMJD3, we
purified JMJD3-associated proteins by tandem affinity purifica-
tion. We expressed double-epitope (Flag-HA) tagged JMJD3 or
UTX in HEK293 cells, and purified interaction partners from
nuclear extracts by Flag- followed by HA-affinity purification (Fig.
S1a). Co-purified proteins were subsequently analysed by mass
spectrometry. From this analysis, we identified p53 as an
interaction partner of JMJD3, but not UTX (Fig.1a). Instead,
UTX co-purified with several members of the MLL3/4 complex
as previously reported [15,30,31] (Fig. S1b). To verify the
interaction between JMJD3 and p53, we transfected Phoenix cells
with plasmids expressing HA-tagged JMJD3 or HA-tagged UTX,
and were able to co-immunoprecipitate (co-IP) p53 only when
overexpressing JMJD3 (Fig. 1b). Moreover, the interaction was
validated between endogenous JMJD3 and p53 in Phoenix cells
(Fig. 1c).
p53 has a domain structure similar to other transcription factors
and possesses an N-terminal transactivating domain, a proline rich
region, a central DNA-binding domain, a tetramerization domain
and a C-terminal regulatory domain. To map the region of p53
required for binding to JMJD3, we tested a number of p53 mutant
proteins (Fig. 1d): p531–360 lacking the C-terminal regulatory
domain; p531–312 lacking the regulatory and the tetramerization
domains; and p5361–312 lacking the regulatory, the tetramerization
and the transactivation domains. As shown in Fig. 1e, the mutants
of p53 lacking the tetramerization domain do not interact with
JMJD3. These data demonstrate an interaction between JMJD3
and p53 that is likely to be mediated either directly through the
p53 tetramerization domain, or that tetramerization of p53 is
required for efficient binding of JMJD3.
Genome-wide mapping of JMJD3 and p53 binding sites
in IR treated BJ cells
Our results indicate that JMJD3 specifically associates with the
tetrameric form of p53, which is the active DNA-binding form of
p53. To understand if JMJD3 and p53 also display genomic co-
localization, we performed global mapping of JMJD3 and p53
binding sites in telomerase-immortalized human BJ diploid
fibroblasts by chromatin immunoprecipitation followed by se-
quencing (ChIP-seq). The experiments were performed in
untreated cells or five hours following exposure to ionizing
radiation (IR). IR generates DNA double-stranded breaks, which
is a potent inducer of the DNA damage response. Following
exposure to IR, p53 was upregulated and phosphorylated on
serine 15 (Fig. 2a), which indicates efficient activation of p53 and
release from MDM2. In addition, JMJD3 protein levels were also
increased in response to IR (Fig. 2a), which is consistent with our
previous results, in which we demonstrated upregulation of JMJD3
in response to UV-induced DNA damage [20]. We also confirmed
here that JMJD3 is upregulated in response to UV damage (Fig
S2a), and verify that the observed interaction between JMJD3 and
p53 still occurs after exposure to either IR or UV damage (Fig S2b
and c).
From the ChIP-seq experiments we found that both p53 and
JMJD3 were bound to significantly more DNA sites following IR
compared to untreated cells (Fig. 2b). Analysis of the ChIP-seq
data by peak detection identified 3232 genomic sites bound by p53
in radiated BJ cells and 35133 JMJD3 binding sites (Fig. 2b),
corresponding to 487 and 5562 unique genes targeted by p53 or
JMJD3 (+/2 5 kb from TSS), respectively (Fig. 2b). Besides
binding to promoters of its target genes, p53 often binds to
response elements several kb upstream of genes or in exon/intron
regions [32,33]. In agreement with this, we found that only 15% of
p53 binding sites were located in promoter regions of annotated
genes (+/2 5 kb from TSS) (Fig. 2c). For JMJD3, we found that
27% of the binding sites were associated with a promoter (Fig. 2c).
At these genes, JMJD3 displayed the strongest binding at the TSS,
with some spreading of the signal into the gene body (Fig. S3a and
S3b). Using available data on the distribution of H3K4me3 and
H3K27me3 in BJ cells [34,35], we found that JMJD3 targeted
promoters were strongly associated with the activating H3K4me3
mark and depleted for H3K27me3 (Fig. S3a and S3c) corre-
sponding to the reported enzymatic activity of JMJD3 and in
agreement with previously reported genome-wide binding data of
JMJD3 obtained in LPS-induced macrophages [19]. Gene
ontology analysis of the identified JMJD3 target genes showed
an enrichment of genes involved in a variety of basic cellular
processes (Fig. 2d), including various metabolic pathways. How-
ever, interestingly, the analysis also identified a subset of JMJD3
target genes involved in regulation of cell cycle, response to stress
and apoptosis. These are all well-known p53 regulated processes,
and consistently, we found that these cellular processes were also
enriched in the identified p53 target genes (Fig. S4). In order to
systematically investigate if JMJD3 exhibits a DNA damage
responsive recruitment to p53 binding sites, we generated a heat
map representing the 3232 identified p53 binding sites (Fig. 2e).
This analysis demonstrated an enrichment of p53 at these binding
sites in response to IR (Fig. 2e and Fig. 2f, upper panel).
Interestingly, we also detected an overall recruitment of JMJD3 to
these target sites in response to IR (Fig. 2e and Fig. 2f, lower
panel).
Taken together, the genome-wide data on p53 and JMJD3
binding demonstrate that both proteins are upregulated and
recruited to DNA sites in response to DNA damage. Although
JMJD3 is bound to more genomic sites than p53, we find that a
P53 Dependent Recruitment of JMJD3 to p53 Binding Sites
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e96545
subset of JMJD3 target genes is involved in the regulation of cell
cycle and apoptosis. In agreement with this, we observe an overall
recruitment of JMJD3 to p53 binding sites in response to DNA
damage.
JMJD3 and p53 co-localize at promoters and distal
regulatory elements
After detecting that a fraction of JMJD3 is associated with p53
binding sites, we focused on p53 binding sites that were located in
gene promoter regions. By overlaying the identified JMJD3 and
p53 promoter-bound genes, we detected a significant overlap of
target genes in irradiated BJ cells (Fig. 3a). In this analysis, 263 p53
target genes were co-bound by JMJD3, which gives a highly
significant overlap between JMJD3 and p53 target genes (p,
1028). These included most of the best-characterised p53 target
genes involved in cell cycle regulation (e.g. CDKN1A (p21),
CCNG1), DNA repair (e.g. GADD45A, DDB2) apoptosis (e.g.
BBC3 (PUMA), TNFRSF10B, TP53INP1) and p53 regulation (e.g.
MDM2) (Fig. 3a). We verified that p53 and JMJD3 are co-
Figure 1. JMJD3 interacts with p53. a, The number of JMJD3, UTX and p53 peptides identified by mass spectrometry in the tandem anti-Flag-HA
purifications of Flag–HA–JMJD3 and Flag-HA-UTX stably expressed in HEK293 cells. b, Phoenix cells were transfected with HA-JMJD3, HA-UTX or an
empty vector (Emp), and immunoprecipitated with an antibody against the HA-tag. Western blotting was performed with antibodies against HA or
p53. c, Co-immunoprecipitation of endogenous JMJD3 and p53 was performed in Phoenix cells by immunoprecipitating with HA (negative control)
or JMJD3 antibody. d, Schematic representation of wild type (wt) p53 and the three p53 deletion mutants lacking the regulatory (REG), the
tetramerization (TET) or the transactivating (TA) domains as indicated. e, Pheonix cells were transfected with myc-tagged JMJD3 alone or together
with wt p53 or p53 deletion mutants as indicated. Immunoprecipitation was performed with myc- or HA antibody followed by western blotting.
doi:10.1371/journal.pone.0096545.g001
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Figure 2. Genome-wide binding of JMJD3 and p53 before and after IR treatment. a, Western blot of JMJD3, p53, p-p53 (p53 serine 15
phosphorylation) and vinculin in human immortalized BJ fibroblasts either untreated or 6 hours after exposure to IR. b, The number of identified
binding sites and target genes for p53 and JMJD3 (defined as binding of p53 or JMJD3 +/2 5 kb from TSS) in untreated or IR exposed cells. c, The
distribution of identified p53 peaks (left panel) or JMJD3 peaks (right panel) in IR treated cells into promoter regions (+/25 kb from TSS), intragenic
regions or intergenic regions (. 5 kb from a gene). d, Gene Ontology analysis of JMJD3 target genes in IR treated BJ cells. e, Heat map of p53 and
JMJD3 ChIP-seq data from untreated or radiated cell representing the 3232 identified p53 binding sites. The heat map is ranked according to the
FDR-value of the p53 peaks. f, The average distribution of p53, JMJD3 and IgG across the centre of all p53 peaks before and after IR.
doi:10.1371/journal.pone.0096545.g002
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recruited to promoters of several target genes, illustrated by ChIP-
seq binding profiles (Fig. 3b) and independent ChIP-qPCR
validations (Fig. 3c). Furthermore, we found that H3K4me3 is
enriched and H3K27me3 is depleted on JMJD3 and p53 targeted
promoters (Fig. S5). Whereas we observed a slight increase of
H3K4me3 levels in response to IR, we did not detect a
corresponding decrease in the levels of H3K27 methylation (Fig.
S5). This is consistent with the observation that both JMJD3 and
p53 appear to be bound (although at lower levels) to several of
their common target genes in the absence of DNA damage (Fig. 2e
and f ).
In addition to binding promoter regions of target genes, we
found that the majority of p53 binding sites are distributed in
inter- and intragenic regions (Fig 2c), indicating that p53 largely
localizes at distal enhancer elements in response to IR. Enhancers
are regulatory DNA elements often located far away from the
genes they act upon. They are characterized by binding of
multiple transcription factors that subsequently recruit co-activator
proteins such as the histone acetyltransferase p300 [36]. Moreover,
the presence of transcription factors at enhancers is associated with
low occupancy of nucleosomes and they are therefore sensitive to
DNase treatment [37,38]. Genome-wide studies have also
Figure 3. IR responsive recruitment of JMJD3 and p53 to promoter regions. a, Venn diagram demonstrating significant (p,1028) overlap
between JMJD3 and p53 target genes in the IR treated BJ cells. At least 263 genes were found to be bound by both JMJD3 and p53 in the promoter
regions, which included several well-known p53 target genes such as CDKN1A, BBC3, TP53INP1, MDM2, GADD45A, RPS27L, CCNG1, TNFRSF10B, and
DDB2. b, Examples of p53 (before and after IR treatment) and JMJD3 (before and after IR treatment) ChIP-seq tracks at BBC3, MDM2, TP53INP1, RPS27L
and HOXB9 (negative control). y-axis of binding profiles denotes number of sequence tag reads. c, The corresponding p53 and JMJD3 ChIP-qPCR
validations at the TSS of the genes listed above.
doi:10.1371/journal.pone.0096545.g003
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demonstrated that enhancers can be annotated based on the
existence of specific histone modifications. Whereas enhancers are
generally depleted for H3K4me3, they are instead associated with
H3K4me1 [39]. Moreover active enhancers are characterized by
high levels of H3K27ac, whereas inactive (transcriptionally poised)
enhancers have increased levels of H3K27me3 [40–42].
To investigate the genomic co-localization of JMJD3 and p53 at
distal p53 binding elements, we divided all p53 binding sites into
promoter-associated sites (, 5 kb from a TSS) or distal p53
binding sites (. 5 kb from a TSS) (Fig. 4a). As shown in Figure 4a,
Jmjd3 is enriched at p53-bound distal elements (Fig. 4a). In fact,
526 distal DNA elements were significantly enriched by both p53
and JMJD3. By including genome-wide data on DNase I
hypersensitivity and H3K4me3 from BJ cells [34,35,43] we
observed that while p53 bound promoters were both DNase I
hypersensitive and associated with H3K4me3, the p53 bound
distal elements were largely depleted from H3K4me3 but still
DNase I hypersensitive (Fig. 4a). Thus, we found that 86% of the
distal DNA elements, which were co-bound by JMJD3 and p53,
overlap with a DNase I hypersensitive site. On the other hand,
only 4% are positive for H3K4me3 (Fig. 4b), indicating that these
sites are likely to represent regulatory enhancer elements.
Furthermore, we validated by ChIP-qPCR that p53 and JMJD3
display an IR responsive recruitment to several putative enhancer
elements (Fig.4c and d and Fig. S6a and S6b). We confirmed that
these sites possess features of active enhancers; they are DNase I
positive (Fig. 4c), show binding of p300 and have enrichment of
H3K4me1 and H3K27ac but not H3K4me3 and H3K27me3
(Fig. 4d). We also observed that exposure to IR correlated with an
increased binding of p300 and subsequently acetylation of H3K27,
which is in agreement with data demonstrating that p53 interacts
with p300 [44].
In summary, these results demonstrate that JMJD3 co-localizes
with p53 at promoters, as well as distal enhancer elements, and
confirms that the binding of p53 and JMJD3 to these sites
increases after exposure to IR.
JMJD3 recruitment to p53 binding sites is dependent on
p53
Although JMJD3 associates with chromatin it does not contain a
known DNA binding domain. Therefore, it is assumed that
JMJD3 depends on other proteins for the specific recruitment to
genomic target sites. p53, on the other hand, contains a DNA
binding domain that specifically recognizes a DNA element known
as the p53 response element. Since we found an increase of JMJD3
binding to p53 genomic binding sites in response to DNA damage,
we investigated if p53 is involved in the recruitment of JMJD3 to a
subset of its binding sites. Therefore, we knocked down p53 in BJ
cells using short hairpin RNA (shRNA) targeting p53 (Fig. 5a).
Both control and p53 knockdown cells were exposed to IR, and
harvested for ChIP assays five hours later. As expected, we
observed significantly lower binding of p53 at targeted promoters
(Fig. 5b) and distal enhancer elements (Fig. 5c) in the p53 depleted
BJ cells compared to control cells. However, we also observed
decreased JMJD3 binding to these sites in the p53 knockdown
cells, demonstrating that p53 is required for efficient binding of
JMJD3 to both promoter regions and distal enhancer elements.
Importantly, we found that JMJD3 enrichment at target genes that
were not bound by p53, were unaffected by depletion of p53
(Fig. 5d), indicating that p53 depletion does not affect the overall
chromatin binding ability of JMJD3, but is involved in the direct
tethering of JMJD3 to sites where the two proteins co-localise.
Potential function JMJD3 binding to p53 target sites
To understand a potential functional role of the observed
recruitment of JMJD3 to p53 genomic targets, we tested different
potential regulatory mechanisms of JMJD3. One possibility is that
JMJD3 contributes to the regulation of p53 methylation, as
previously suggested using an antibody raised to methylated lysine
[29], but not confirmed in an independent study [28]. The C-
terminal part of p53 is methylated at lysine residues K370, K372,
and K382 [45–47] and was demonstrated to be demethylated by
the histone lysine demethylase LSD1 at K370me2 [48]. To test if
JMJD3 can demethylate p53 on any of these sites, we purified
recombinant catalytically active JMJD3 (JMJD3s, amino acids
1027–1685) (Fig. S7a and S7b) [11]. Next we incubated
recombinant JMJD3s with H3K27me3 synthetic peptide (amino
acids 20–34) or p53 peptides (amino acids 367–388) with the
following modifications: unmodified, K370me2, K372me1,
K372me2, K372me3, K373me2, K381me1, K381me2,
K381me3, K382me1, K382me2, K382me3 or K386me2, and
analyzed the samples by MALDI-TOF mass spectrometry.
Whereas, JMJD3 efficiently catalysed demethylation of the
H3K27me3 peptide (Fig. S8a), no detectable activity was observed
with any of the tested p53 peptides (Fig. S8b). These results
disfavour a role for JMJD3 in the regulation of p53 C-terminal
methylation, however, we cannot rule out that JMJD3 is involved
in regulating p53 methylation at other lysine residues than the
tested ones, or that additional co-factors are required for an
efficient enzymatic removal of methylation.
As previously mentioned, we were unable to detect a decrease in
H3K27me3 levels after recruitment of JMJD3 to p53 target sites
(Fig. S5). Also, when estimating the overall levels of H3K27me3 at
p53 targeted promoters and enhancers, we found that these were
generally depleted of H3K27me3 (Fig. S9). These data indicate
that JMJD3 is not involved in demethylating high levels of
H3K27me3 at p53 binding sites. Moreover, we also tested if
depleting JMJD3 in the BJ cells had an effect on the transcription
of p53 target genes. However, a 50–70% knockdown of JMJD3
(mRNA and protein levels, respectively) (Fig. S10a and S10b) did
not cause any detectable changes of the expression of selected p53
target genes after DNA damage (Fig. S10c). Furthermore, JMJD3
knockdown did not affect the protein levels of p53 (Fig S2a and
S10a). Taken together, these data suggest that JMJD3, under these
conditions, is not a major regulator of p53 transcriptional
activation of target genes or p53 protein stability.
Based on our data, we propose a model where JMJD3 is
recruited to p53 bound promoters and distal enhancer elements
via an interaction with the p53 tetramer, which simultaneously
recruits the histone acetyltransferase p300 (Fig. 6). We speculate
that JMJD3 could serve as a fail-safe mechanism to remove low
levels of slowly accumulating H3K27me3 or H3K27me2.
However, we cannot rule out that that JMJD3 could have histone
demethylase independent roles such as in the recruitment of other
effector proteins or in the demethylation of non-histone targets
(Fig. 6).
Discussion
The expression of the H3K27me3/me2 demethylase JMJD3 is
increased in response to different stimuli such as differentiation
inducers and stress signals. It has been linked to the regulation of
numerous biological processes including embryonic stem cell
differentiation, inflammatory response in macrophages and
regulation of the INK4A-ARF locus during stress. With its tissue
specific and highly inducible expression, JMJD3 appears to
function in well-defined and restricted cellular processes, which
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is unlike UTX that is ubiquitously expressed and suggested to
function as a ‘‘housekeeping’’ demethylase. However, little is
known about the direct function of JMJD3 in transcriptional
regulation. Here we show that JMJD3 interacts with the tumour
suppressor protein p53, and that JMJD3 localises to p53 bound
promoters and enhancers in a p53-dependent manner.
By purifying JMJD3 and UTX associated proteins, we identified
p53 as an interaction partner of JMJD3, which is consistent with
recent studies [27–29]. For UTX, on the other hand, we did not
observe an interaction with p53, but instead purified several
members of the MLL3/4 complex. This is in agreement with
previously reported data [15,30,31]. We did not find significant
enrichment of MLL proteins in the JMJD3 complex purification,
indicating that UTX and JMJD3 associate with distinct protein
complexes.
Figure 4. IR responsive recruitment of JMJD3 and p53 to distal enhancer elements. a, Heat map representing p53 binding sites divided
into promoter associated (, 5 kb from a TSS, 487 peaks) or distal binding sites (. 5 kb from a TSS, 2745 peaks). b, Venn diagrams illustrating the
overlap between p53 and JMJD3 co-bound distal elements and DNase I hypersensitive sites (left panel) or H3K4me3 positive regions (right panel). c,
Examples of p53 (before and after IR treatment) and JMJD3 (before and after IR treatment), H3K4me3 and DNase I-seq [34,35,43] tracks at two
putative enhancer elements located 11 kb upstream of CDKN1A (upper panel) or 19 kb upstream of GML (lower panel). d, Corresponding ChIP-qPCR
validations of the binding of p53, JMJD3 and p300 as well as the levels of histone modifications H3K4me1, H3K4me3, H3K27ac and H3K27me3 at the
two distal binding sites listed above.
doi:10.1371/journal.pone.0096545.g004
Figure 5. JMJD3 binding to p53 binding sites is dependent on p53. a, Western blot of control (ctrl) or p53 knockdown (shp53) cells. The cells
were exposed to IR and harvested for ChIP-qPCR assays after five hours. b and c, ChIP-qPCR data demonstrating the binding of p53 and JMJD3 to the
promoters of p53 target genes BBC3, TP53INP1, MDM2, and RPS27L (b) or to the CDKN1A -11 kb and GML -19 kb distal elements (c) in control or p53
knockdown cells. d, ChIP-qPCR data demonstrating the binding of p53 and JMJD3 to HIST1H3E and EIF3B, which are not p53 target genes.
doi:10.1371/journal.pone.0096545.g005
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We further characterised the interaction between JMJD3 and
p53 by cloning different p53 deletion mutants. We found that the
tetramerization domain of p53 is required for the interaction
between p53 and JMJD3. Moreover, we performed genome-wide
mapping of JMJD3 and p53 by ChIP-seq in telomerase
immortalized BJ fibroblasts after exposure to IR, which induces
DNA damage and p53 activation. Here we found that JMJD3
associates with genes involved in basic cellular processes, but also
genes involved in cell cycle regulation, stress responses and
apoptosis. In agreement with this, we observed a significant
overlap of JMJD3 and p53 target genes, which included several
well-characterised p53 responsive genes. In addition, we found
that JMJD3 co-localizes with p53 at its distal binding sites, which
are likely to represent enhancer elements. We found that JMJD3 is
upregulated in response to DNA damage and that the binding of
JMJD3 to both p53 targeted promoters and enhancers increases
after IR treatment. Furthermore, we were able to demonstrate that
the binding of JMJD3 to p53 binding sites is dependent on p53,
and thereby we provide a potential recruitment mechanism for
JMJD3 to a subset of its target genes.
We also tested if JMJD3 could be involved in demethylating
p53. p53 is methylated at C-terminal lysine residues: K370, K372
and K382. Interestingly, the enzymes responsible for p53
methylation, SET9 [45], SMYD2 [46] and SET8 [47], are
enzymes that also target histone tails. In line with this, the histone
lysine demethylase LSD1 was reported to demethylate p53
K370me2 [48]. We therefore tested the ability of JMJD3 to
demethylate p53 C-terminal peptides that were mono-, di- or tri-
methylated at several lysine residues. However, whereas we found
a clear demethylation of H3K27me3 peptide, we did not detect
demethylation of any of the tested p53 peptides. These data
suggest that JMJD3 is not involved in demethylating the C-
terminal part p53. However, there could still be undiscovered
methylation sites in the p53 protein that are targeted by JMJD3
demethylase activity. Alternatively, JMJD3 could be involved in
demethylating other non-histone proteins localised at p53 target
genes.
Based on our observations, we propose a model where JMJD3
binds to p53 responsive elements via its association with the p53
tetramer. We did not find a correlating decrease in H3K27me3
after the increased binding of JMJD3 to p53 target genes. This is
consistent with data reported by De Santa et al., who investigated
the recruitment of JMJD3 to target genes in inflammatory
stimulated macrophages and did not find any correlation between
JMJD3 recruitment and changes in H3K27me3 levels [19].
Furthermore, JMJD3 has been shown to have demethylase
independent roles in chromatin remodelling [49] and in its
negative regulation of reprogramming of somatic cells into
induced pluripotent stem cells [50]. Taken together, these results
suggest a demethylase independent role of JMJD3 similar to what
has been described for other demethylases, including UTX
[51,52].
In a recent study in which the role of p53 during differentiation
and DNA damage of human embryonic stem cells is investigat-
ed[27], the authors found genes associated with p53 during
differentiation to show a corresponding decrease in H3K27me3
levels. These results suggest that, p53 target genes, under certain
circumstances, could be regulated by H3K27me3. Moreover,
these observations could give mechanistically insight to the
observed interaction between p53 and JMJD3. The lack of
H3K27me3 demethylation after recruitment of JMJD3 to p53
target genes in our study could be explained by the fact that we
often observe that both p53 and JMJD3 are bound to their target
genes even before DNA damage. Therefore, we speculate that
JMJD3 could acts as a fail-safe mechanism to maintain the levels of
H3K27me3 low and permissible for H3K27ac by p300 at p53
response elements, rather than contributing to the direct activation
of target genes. This mechanism could be especially important at
enhancer regions, which has been suggested to be regulated by the
switch between H3K27 methylation and acetylation. Interestingly,
a few reports have linked JMJD3 to the regulation of enhancer
activity. For example, JMJD3 was suggested to regulate
H3K27me3 levels at an enhancer element driving the expression
of the BCL2 gene in breast cancer cells [53]. Another study
demonstrated the requirement of JMJD3 recruitment to an
enhancer element regulating a-globin expression, in order to
mediate PRC2 eviction and loss of H3K27me3 [54].
Within the last decade, the regulatory functions of p53 have
expanded from cell cycle arrest and apoptosis to also include
metabolism, aging, embryo implantation and quiescence of stem
cells [55,56]. It is therefore likely that the importance of JMJD3 in
p53 transcriptional regulation would be more pronounced when
investigating other p53 regulated pathways than the IR induced
DNA damage response, as was the case in our study. Indeed,
understanding the molecular mechanisms involved in p53
mediated transcriptional regulation is of great interest in order
Figure 6. Model of the potential roles of JMJD3 in regulating p53 target genes. JMJD3 is recruited to p53 bound promoters and distal
enhancer elements via an interaction with the p53 tetramer, which simultaneously recruits the histone acetyltransferase p300. JMJD3 could be
involved in adjusting p53 transcriptional regulation by demethylating H3K27me3/me2, demethylating other non-histone proteins, or by having
catalytically independent functions. See text for further details.
doi:10.1371/journal.pone.0096545.g006
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to gain insight into the important tumour suppressive functions of
p53, as well as its expanding roles in metabolism, cellular
homeostasis and differentiation. Hopefully, future studies will help
unravel the exact role of JMJD3 in the complex network of p53
transcriptional signalling.
Materials and Methods
Cell culture and DNA damage
A telomerase-immortalized version of the human diploid BJ
fibroblast cell line (ATCC number CRL-4001), HEK293 cells
[57], and Phoenix cells [58] were cultured in D-MEM (Gibco)
supplemented with 10% FBS (Hyclone), penicillin and streptomy-
cin. Recombinant lentiviruses encoding p53 shRNA [59] were
produced by standard methods employing transfection of pRe-
troSuper shRNA in Phoenix-ampho cells. shRNA-transduced BJ
cells were selected 36 h post transduction with 2 mg per ml of
puromycin for 72 h. To generate DNA damage, BJ cells were
exposed to 10 Gy of ionizing radiation delivered by X-ray
generators (Faxitron CP160, 160 kV, 6.3mA and Faxitron
RX650, 130 kV, 3 mA).
Cloning Procedures
JMJD3 and UTX were cloned as previously described [11]. Wt
p53 and p53 deletion mutants were PCR-amplified from human
p53 clone [60] and introduced into the Gateway Entry vector
pCR8/GW/TOPO (Invitrogen) following the manufacturer’s
protocol. The different constructs were subcloned in the desired
vectors by Gateway technology (Invitrogen).
Purification of JMJD3 and UTX complexes
In order to isolate JMJD3 and UTX-containing complexes,
two-step affinity purification was performed followed by mass
spectrometry analysis. HEK293 cells stably expressing doxycycline
(DOX)-inducible amino-terminally Flag and HA-tagged JMJD3 or
UTX were generated using the HEK293 Flp-In TREx cells as
described by the manufacturer (Invitrogen). Nuclear extracts (250–
500 mg, 36109 cells) from the HEK293 cell lines were precleared
and incubated with a 700 ml packed volume of anti-Flag-beads
(Anti-Flag M2-agarose, Sigma) overnight at 4 uC with rotation.
The beads were collected by centrifugation at 7006 g for 5 min
and washed 6 times with 40 6 resin bed volume of buffer A
(20mM Tris-HCl, pH 8.0, 300 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 10% glycerol, 0.2 mM PMSF, 1 mM DTT,
1 mg/ml aprotinin and 1 mg/ml leupeptin). The beads were
transferred into a 10 ml poly-prep chromatography column (Bio-
Rad) and complexes were then eluted five times after 10 min of
incubation using one resin bed volume of buffer A supplemented
with 0.5 mg/ml Flag peptide. The eluate was subjected to a second
round of purification using an antibody against the HA-tag. The
Flag-IP elute was incubated with 200 ml of a 50% slurry of HA-
beads overnight. The beads were washed four times with buffer A
and eluted with 100 ml buffer A supplemented with 1 mg/ml HA
peptide for two hours. Small aliquots of the eluted proteins were
run on SDS-PAGE gels and subjected to silver staining using the
SilverQuest kit (Invitrogen) according to manufacturer’s instruc-
tions. The rest of the samples were boiled in SDS loading buffer
and run shortly into a SDS-PAGE gel in order to remove the Flag
and HA peptide and other contaminations. A gel slice containing
the purified proteins was isolated for mass spectrometry analysis.
Antibodies
The JMJD3 antibody was generated in rabbits, using affinity-
purified GST-JMJD3 (amino acids 798–1095) as described in [20].
Other antibodies used included p53 (DO-1), p-p53 (Cell Signaling,
#9284), p300 (Santa Cruz, Sc-585) H3 (Abcam, Ab1791),
H3K4me1 (Abcam, Ab8895), H3K4me3 (Cell Signaling,
#9751), H3K27ac (Milipore, 07-360), H3K27me3 (Cell Signaling,
#9733) and Vinculin (Sigma-Aldrich, V9131).
Co-immunoprecipitation experiments and WB analysis
Co-mmunoprecipitation experiments were performed using
1 mg of cell extracts in E1A buffer (50 mM Hepes buffer
pH 7.5, 250 mM NaCl, 0, 5 mM EDTA, 0.1% TritonX100,
Leupeptin, Aprotinin and 1 mM PMSF) as described earlier [61]
using the indicated antibodies. Protein extracts for western blot of
p53 and JMJD3 were made using RIPA buffer (25 mM Tris-HCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, Leupeptin, Aprotinin and 1 mM PMSF) and
sonication. Immunoblotting was performed according to standard
protocols.
ChIP and ChIP-seq
ChIP-seq experiments were performed as previously described
[61]. ChIP-seq data are available at the Gene Expression
Omnibus (GEO) (accession number GSE55912).Tags were
aligned to the human genome (hg18 assembly) using Bowtie
version 0.12.7 [62] with default parameters except ‘‘-S -m 1’’. Peak
detection for JMJD3 and p53 datasets was performed in MACS
version 2 [63], using sequencing reads from an IgG control
experiment as negative control. When generating bigwig files we
allowed only one read per chromosomal position thus eliminating
potential spurious spikes. Each remaining read was extended from
its 59-end to a total length of 250 bases. Each bigwig file was also
scaled to TPM (Tags Per Million) based on the number of unique
read positions. Heat map and binding profiles across genomic
regions were generated using the SeqMiner program [64], where a
constant read number between samples was employed for
comparison. Gene Ontology classifications were performed using
the Panther program [65]. Primers for ChIP-qPCR analyses were
designed using the Primer3 software and real-time quantitative
PCR was performed on a Roche LightCycler 480 II detection
system using SYBR Green qPCR Master Mix (Fermentas).
Purification of recombinant JMJD3
Recombinant JMJD3 was generated by co-transfection of
baculovirus transfer-vector containing a Flag-tagged fragment of
human JMJD3 (JMJD3s, amino acids 1027-1685) and Bsu36I
linearized Bakpak6 baculovirus DNA. Insect cells were incubated
at 28uC and harvested 40–44 h post infection, washed twice in
PBS, resuspended in 30 ml of lysis buffer (25 mM HEPES-NaOH
pH 7.5, 300 mM NaCl, 1.5 mM MgCl2, 10% Glycerol, 0.2%
TritonX100, Leupeptin, Aproteinin), sonicated and cleared by
centrifugation at 20,000 g for 30 min. After filtrating the lysate
through a 0.45 mM filter, it was loaded onto a 10 ml poly-prep
chromatography column (Bio-Rad) packed with 0.5 ml packed
volume of Flag-beads. The column was washed with 2610 ml of
lysis buffer and eluted in buffer supplemented with 0.5 mg/ml Flag
peptide. The eluted fractions were analysed by SDS-PAGE, flash
frozen in liquid N2 and stored at 280uC.
Demethylation assay
Demethylation assays were performed on calf thymus histones
(Sigma Aldrich) or synthetic peptides H3K27me3 (amino acids 20-
34: LATKAARKSAPATGG) or p53 (amino acids 367–388:
SHLKSKKGQSTSRHKKLMFKTE) with the following modifi-
cations: unmodified, K370me2, K372me1, K372me2, K372me3,
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K373me2, K381me1, K381me2, K381me3, K382me1,
K382me2, K382me3 or K386me2. 15 mg of histones or 4 mg of
peptides were incubated with purified Flag-JMJD3s for 60 min at
37uC in demethylation buffer (25 mM Tris pH8, 1.5 mM
MagCl2, 50 mM NaCl, 1 mM a-Ketoglutaric acid, 2 mM
Ascorbic acid, 40 mM FeSO4) in a final volume of 100 ml. For
analysis of histones increasing amount of recombinant Flag-
JMJD3s (0–30 mg) were used and reaction mixtures were analysed
by western blotting using specific antibodies against H3K27me2,
H3K27me3, or H3K4me3. For peptide analysis 30 mg of
recombinant Flag-JMJD3s were added. After incubation in
demethylation buffer the peptide samples were added 1/10
volume 1% TFA, and desalted on a mC18 ZipTips (Millipore)
following the suppliers instructions. Peptides were eluted in a
saturated solution of a-cyano-4-hydroxycinnamic acid in 65%
acetonitrile, in Milli-Q water containing 0.1% TFA. 1 ml was
spotted onto the target and air-dried for 15 min at rt. The
MALDI-TOF MS was carried out on an Ultraflex TOF/TOF
(Bruker) operated in positive ion mode with an ion source voltage
of 25 kV, a lens voltage of 7.5 kV and a reflector voltage of
26.3 kV. The system was run in deflection mode with a mass
suppression of 500 Da. The data analysis was carried out using the
FlexAnalysis software (Bruker). Baseline subtraction and smooth-
ing of the curves were applied.
Supporting Information
Figure S1 Purification of Flag-HA-JMJD3 and Flag-HA-
UTX complexes. a, Silver-stained SDS-PAGE of Flag- and
Flag-HA-purified complexes from HEK293 cells stably expressing
Flag-HA-JMJD3 or Flag-HA-UTX. The arrows indicate the
position of Flag-HA-JMJD3 or Flag-HA-UTX. b, The number of
peptides identified by mass spectrometry for JMJD3, UTX,
MLL4, MLL3, RBBP5, WDR5, ASH2L, PTIP, DPY-30 and
p53 in the Flag-HA tandem purifications.
(EPS)
Figure S2 JMJD3 is upregulated and interacts with p53
after UV damage. a, Western blot of JMJD3, p53, and vinculin
in human immortalized BJ fibroblasts either untreated or 6, 12 or
24 hours after exposure to UV. b, Co-immunoprecipitation of
endogenous JMJD3 and p53 was performed in Phoenix cells by
immunoprecipitating with HA (negative control) or JMJD3
antibody before or after 5 h of IR (10 Gy). c, Co-immunoprecip-
itation of endogenous JMJD3 and p53 performed in Phoenix cells
by immunoprecipitating with HA (negative control) or p53
antibody before or after 5 h of UV (50 J/m2).
(EPS)
Figure S3 Characterization of JMJD3 target genes. a,
Heat map of JMJD3 (before and after IR treatment), H3K4me3
and H3K27me3 [34,35] at all identified JMJD3 target genes in IR
treated BJ cells. b, Average binding profile of JMJD3 across the
TSS of its target genes. c, Average distribution of H3K4me3 and
H3K27me3 at JMJD3 target genes.
(EPS)
Figure S4 Gene Ontology analysis of identified p53
target genes. Gene Ontology analysis of the p53 target genes
identified in the IR treated BJ cells (defined as genes bound by p53
+/- 5 kb from TSS).
(EPS)
Figure S5 Investigation of histone modifications at p53
bound promoters. ChIP-qPCR assays estimating the levels of
H3, H3K4me3, and H3K27me3 at p53 target genes BBC3,
RPS27L, CDKN1A, CCNG1, MDM2, SPATA18, TP53INP1, and the
repressed HOXB9 gene that is not bound by p53 or JMJD3.
(EPS)
Figure S6 IR responsive recruitment of JMJD3 and p53
to distal enhancer elements. a, Examples of p53 (before and
after IR treatment) and JMJD3 (before and after IR treatment),
H3K4me3 and DNase I-seq [34,35,43] tracks at two putative
enhancer elements located 12 kb upstream of ATF3 (upper panel)
or at genomic position chr4:153,399,193-153,401,046 (lower
panel). b, Corresponding ChIP-qPCR validations of the binding
of p53, JMJD3 and p300 as well as the levels of histone
modifications H3K4me1, H3K4me3, H3K27ac and H3K27me3
at the two distal binding sites listed above.
(EPS)
Figure S7 Purification of recombinant catalytically
active JMJD3. a, Samples of purified recombinant JMJD3
(JMJD3s, amino acids 1027-1685) were subjected to SDS-PAGE
and stained using Coomassie blue. The arrow indicates the
position of recombinant JMJD3. b, The activity of recombinant
JMJD3 was tested in vitro by incubating histones with increasing
amounts of recombinant JMJD3 in demethylase buffer. The
samples were analysed by western blotting for H3K27me3,
H3K27me2 and H3K4me3.
(EPS)
Figure S8 Demethylation of H3K27me3 or p53 peptides.
a and b, H3(20-34)K27me3 (a) or p53 (unmodified, K370me2,
K372me1, K372me2, K372me3, K373me2, K381me1,
K381me2, K381me3, K382me1, K382me2, K382me3 or
K386me2) (b) peptides were incubated with or without recombi-
nant JMJD3 and analysed by mass spectrometry. A shift in mass
equivalent to one methyl-group is indicated by dashed lines.
(EPS)
Figure S9 p53 binding does not correlate with
H3K27me3. a, Heat map of p53 and H3K27me3 [34,35] at
p53 bound promoters (, 5kb from TSS) or p53 distal binding sites
(. 5kb from TSS) in IR treated BJ cells. b, Average distribution of
H3K27me3 and p53 across p53 promoter associated or distal
binding sites.
(EPS)
Figure S10 Expression of p53 target genes after JMJD3
knockdown. a, Western blot of JMJD3, p53, and vinculin in
human immortalized BJ fibroblasts transfected with a control
siRNA (siScr) or a siRNA targeting JMJD3 (siJMJD3). b and c,
qRT-PCR data illustrating the expression of JMJD3 (b), CDKN1A,
BBC3 and GADD45A (c) in control or JMJD3 knockdown cells
before or 6 and 24 h after IR treatment.
(EPS)
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